IP Library › Granted Patent US 8,055,452
Granted Patent B2
US 8,055,452 · App. 12/609,578 · Granted Nov 8, 2011

Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Assignee: Life Technologies Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,055,452
App. No.
12/609,578
Granted
Nov 8, 2011
Kind
B2
Abstract

A method provides an index that is indicative of the state of a subject, as to a biological condition, based on a sample from the subject. An embodiment of this method includes: deriving from the sample a profile data set, the profile data set including a plurality of members, each member being a quantitative measure of the amount of a distinct RNA or protein constituent in a panel of constituents selected so that measurement of the constituents enables evaluation of the biological condition; and in deriving the profile data set, achieving such measure for each constituent under measurement conditions that are substantially repeatable; and applying values from the profile data set to an index function that provides a mapping from an instance of a profile data set into a single-valued measure of biological condition, so as to produce an index pertinent to the biological condition of the subject.

Claims (10)

1. A method of predicting change in a biological condition of a subject as a result of exposure to an agent, the method comprising:

a) producing a first index for a sample from the subject in the absence of the agent, the sample providing a source of RNAs comprising:

i) using amplification for quantitatively measuring the amount of RNA of at least two constituents from any one of Tables 1 through 12 from the sample from the subject, wherein a panel of constituents is selected so that measurement conditions of the constituents enables evaluation of said biological condition and wherein the measures of all constituents in the panel form a first profile data set, wherein said amplification for each constituent is under conditions that are (1) within a degree of repeatability of better than five percent; and (2) the efficiencies of amplification are within two percent;

ii) using amplification for quantitatively measuring the amount of RNA of all constituents in said panel wherein the measures of all constituents in the panel are from a relevant population of subjects and form a normative baseline profile data set; and

iii) applying values from the first profile data set to an index function derived using latent class modeling, thereby providing a single-valued measure of the biological condition so as to produce an index pertinent to the biological condition of the subject;

wherein the index function also uses data from the normative baseline profile data set,

b) producing a second index for a second sample from the subject in the presence of the agent, the second index based on the same panel of constituents; and

c) using the first and second indices to predict change in the biological condition of the subject as a result of exposure to the agent.

2. A method according to claim 1 , wherein the agent is a compound.

3. A method according to claim 2 , wherein the compound is therapeutic.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2011
From: SOURCE PRECISION MEDICINE, INC. D/B/A SOURCE MDX
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 026238/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2009
From: BANKAITIS-DAVIS, DANUTE
To: SOURCE PRECISION MEDICINE, INC.
Reel/Frame 023669/0556 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2009
From: BEVILACQUA, MICHAEL; CHERONIS, JOHN C.; TRYON, VICTOR
To: SOURCE PRECISION MEDICINE, INC.
Reel/Frame 023669/0634 →
Continuity (7)
Continuation 11158504 · Jun 22, 2005
Continuation 10291856 · Nov 8, 2002
Provisional Application 60348213 · Nov 9, 2001
Provisional Application 60340881 · Dec 7, 2001
Provisional Application 60369633 · Apr 3, 2002
Provisional Application 60376997 · Apr 30, 2002
Related Publication 20100086935A1 · Apr 8, 2010